Search / Trial NCT06233357

Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application

Launched by UNIVERSITY OF ULM · Jan 22, 2024

Trial Information

Current as of December 21, 2024

Completed

Keywords

Covid 19 Critically Ill Icu Casirivimab Imdevimab Tocilizumab Interleukin 6 C Reactive Protein Ferritin Procalcitonin Mortality

ClinConnect Summary

According to the recommendations, IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight. 28-day mortality and 30-day time course of leukocyte counts and serum concentrations of C-reactive protein (CRP), procalcitonin (PCT), interleukin 6 (IL-6) and ferritin in 4 patient groups, i. e., treated without (N) or with casirivimab / imdevimab (C) or tocilizumab (T),...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Clinical diagnosis of COVID-19
  • CoV-2 delta-variant
  • critically ill patients
  • ICU
  • Exclusion Criteria:
  • tuberculosis
  • active hepatitis
  • HIV

Trial Officials

Manfred Weiss, MD

Principal Investigator

University of Ulm

About University Of Ulm

The University of Ulm is a leading academic institution located in Germany, renowned for its commitment to cutting-edge research and innovation in the fields of medicine and health sciences. As a clinical trial sponsor, the university leverages its robust network of researchers and clinical experts to advance medical knowledge and improve patient outcomes. With a focus on interdisciplinary collaboration, the University of Ulm conducts comprehensive clinical studies that adhere to the highest ethical standards and regulatory guidelines. Through its research initiatives, the university aims to contribute significantly to the development of new therapies and treatment modalities, fostering a deeper understanding of various health conditions.

Locations

Ulm, , Germany

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0